Phosphorylated ERK1/2 allows the activation of the typical apoptotic factor, p53 [22,23,24], which expression is assessed in both tumor cell lines after 1 h of treatment with SLC-0111 and AA-06-05. The gene discussed is MAPK3; the disease is neoplasm.